ホーム › 腎臓がん（腎細胞がん） › マサチューセッツ州 › Boston
Boston、MAにおける腎臓がん（腎細胞がん）の臨床試験
Bostonとその周辺地域（約30マイル以内）の拠点で、腎臓がん（腎細胞がん）に関する16件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
被験者募集中第1相
- Research Site, Boston
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
被験者募集中第1相
- Exelixis Clinical Site #7, Boston
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
被験者募集中第1/2相
- Tufts Medical Center, Boston
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
被験者募集中第2相
- Massachusetts General Hospital Cancer Center, Boston
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
被験者募集中第1/2相
- Brigham and Women's Hospital, Boston
- Dana Farber/Mass General Brigham Cancer Care, Inc, Boston
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
被験者募集中第3相
- Tufts Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma
被験者募集中第2相
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
被験者募集中第1相
- Dana-Farber Cancer Institute, Boston
A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
被験者募集中第1相
- Dana-Farber Cancer Institute, Boston
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
被験者募集中第1/2相
- Massachusetts General Hospital, Boston
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
被験者募集中第1相
- Dana-Farber Cancer Institute, Boston
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
被験者募集中第1相
- Beth Israel Deaconess Medical Center /ID# 252009, Boston
- Dana-Farber Cancer Institute /ID# 249642, Boston
Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma
被験者募集中第2相
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Drug Screening Using Novel IMD in Renal Cell Carcinoma
被験者募集中第1相
- Dana-Farber Cancer Institute, Boston
Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC
被験者募集中第2相
- Beth Israel Deaconess Medical Center, Boston
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
被験者募集中第1/2相
- Massachusetts General Hospital, Boston
他の都市における腎臓がん（腎細胞がん）の試験
- Houston, TX35件の研究
- New York City, NY27件の研究
- Nashville, TN23件の研究
- Dallas, TX23件の研究
- St. Louis, MO23件の研究
- Los Angeles, CA20件の研究
- Baldwin Park, CA16件の研究
- Philadelphia, PA15件の研究
- Pittsburgh, PA15件の研究
- Queens, NY15件の研究
- Jacksonville, FL14件の研究
- Cleveland, OH14件の研究
Bostonにおける他の研究
- 乳がん112件の研究
- 非小細胞肺癌90件の研究
- がん（全種類）85件の研究
- 転移性癌63件の研究
- 大腸癌63件の研究
- 肺がん62件の研究
- 卵巣がん61件の研究
- 前立腺がん59件の研究
- うつ病52件の研究
- 子宮内膜がん50件の研究
- 心不全44件の研究
- 急性骨髄性白血病44件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。